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Abstract 
Background: Residual risk of cardiovascular disease from increased small dense low-density 
lipoprotein (sdLDL)-cholesterol and n-3 polyunsaturated fatty acid (PUFA) levels are a 
considerable therapeutic issue. The purpose of this study was to evaluate the effect of ezetimibe 
as an add-on to statins and supplemental eicosapentaenoic acid (EPA) on sdLDL-cholesterol and 
absorption of EPA in patients with coronary artery disease. 
Methods: The study population consisted of 10 male patients who were concurrently receiving 
statins and EPA 1800 mg/day. Serum lipids and PUFAs, including EPA and arachidonic acid, 
were measured in blood samples collected before ezetimibe (baseline), 4 weeks after starting 
10-mg/day ezetimibe, and 4 weeks after discontinuing ezetimibe. 
Results: Ezetimibe significantly decreased sdLDL-cholesterol levels after 4 weeks of treatment 
(baseline, 35 ± 13 mg/dl; treatment, 27 ± 9 mg/dl), but the levels returned to baseline after 
discontinuation of ezetimibe (37 ± 13 mg/dl). The concentration of EPA did not significantly 
change during the study. 
Conclusion: Ezetimibe shows great promise as an add-on therapy to statins to reduce 
sdLDL-cholesterol–related residual risk of cardiovascular disease without affecting absorption of 
supplemental EPA in patients with coronary artery disease. 
 
Key Points: Ezetimibe may be useful for secondary prevention of cardiovascular disease in 
patients with atherogenic dyslipidemia without affecting absorption affecting supplemental 
eicosapentaenoic acid, which is potentially preventive agent for cardiovascular disease.  
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Introduction 
Decreasing low-density lipoprotein (LDL)-cholesterol levels is the primary goal in the 
management of dyslipidemia in patients at high risk of cardiovascular disease [1-3]. Despite the 
use of statins which enable the achievement of targeted LDL-cholesterol levels, a substantial 
number of coronary events still occur [4, 5], which may result, in part, from elevated levels of 
triglycerides and triglyceride-rich lipoprotein remnants, and low levels of high-density 
lipoprotein (HDL)-cholesterol, which are often accompanied by high levels of small, dense LDL 
(sdLDL)-cholesterol. This combination is referred to as atherogenic dyslipidemia [6], which is 
highly prevalent in patients with diabetes mellitus or metabolic syndrome. In the Effect of 
Potentially Modifiable Risk Factors Associated With Myocardial Infarction in 52 Countries 
(INTERHEART) study, the risk associated with atherogenic dyslipidemia was shown to be 
independent to LDL-cholesterol levels [7]. To reduce the risk of coronary artery disease (CAD) 
further, secondary therapies to increase HDL-cholesterol, decrease triglycerides and 
triglyceride-rich lipoprotein remnants, and lower sdLDL-cholesterol levels may be recommended 
for patients who had achieved LDL-cholesterol levels below the currently recommended targets. 
Ezetimibe, a cholesterol-absorption inhibitor, is used as an alternative to statins and as an 
add-on therapy for the reduction of LDL-cholesterol levels [8-10]. Ezetimibe decreases 
sdLDL-cholesterol levels when used in combination with statins[11, 12], whereas 
eicosapentaenoic acid (EPA), an n-3 polyunsaturated fatty acid (PUFA), has been shown to lower 
sdLDL-cholesterol levels, alone or in combination with statins [13, 14]. Thus, combined 
treatment with a statin, ezetimibe, and EPA may have the potential to lower triglycerides and 
sdLDL-cholesterol levels in patients with atherogenic dyslipidemia. However, the effects of this 
triple therapy on sdLDL-cholesterol levels have not been fully elucidated. In addition, a previous 
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animal study showed that ezetimibe significantly reduced absorption of dietary saturated fatty 
acids, but only a small effect was observed for the unsaturated fatty acids [15]. In humans, the 
effect of ezetimibe on absorption of EPA remains unclear. 
The aim of this study was to evaluate if ezetimibe, as an add-on therapy to statin and EPA 
therapy, could lower sdLDL-cholesterol levels in patients with CAD, and if add-on ezetimibe 
affects the absorption of supplemental EPA. 
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Methods 
Participants and design. 
This study was approved by the Ethics Committee of Okayama University Hospital and 
Tamashima Central Hospital, and written informed consent was obtained from all participants 
before beginning the protocol. This study was conducted according to the principles expressed in 
the Declaration of Helsinki. The study is registered at UMIN Clinical Trials Registry 
(UMIN000012589). Schema of the study design is shown in Fig. 1. 
This prospective study consisted of 10 outpatients with CAD who visited Tamashima Central 
Hospital (Okayama, Japan) regularly from May 2013 to November 2013. All enrolled patients 
had been receiving a statin and EPA (1800 mg/day) for dyslipidemia and secondary prevention of 
CAD for >3 months. Patients were excluded from the study if they had experienced acute 
coronary syndromes, stroke, or heart failure; had undergone major surgery <3 months before 
enrollment; or had variant angina, concomitant inflammatory diseases, or malignant tumors. 
Hypertension was defined as a seated blood pressure ≥140/90 mmHg or current use of 
antihypertensive agents. Diabetes was defined as fasting blood glucose ≥126 mg/dl and 
hemoglobinA1c ≥6.5%, or as requiring antidiabetic agents. Dyslipidemia was diagnosed 
according to the 2012 Japan Atherosclerotic Society guidelines or as concurrent treatment with a 
cholesterol-lowering agents[16]. Pre-specified primary outcome measure was the difference in 
sdLDL-cholesterol after ezetimibe treatment, and secondary outcome measure was the difference 
in n-3 PUFAs after ezetimibe treatment. Blood samples were collected prior to ezetimibe 
administration (baseline), 4 weeks after starting ezetimibe, and 4 weeks after discontinuation of 
ezetimibe. 
Blood Examination. 
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Venous blood samples were obtained from the patients when they visited the outpatient clinic 
after overnight fasting for 8–12 hours. Serum lipid (total cholesterol, HDL-cholesterol, and 
triglyceride were measured using an autoanalyzer and routine methods at the central laboratory of 
Tamashima Central Hospital. LDL-cholesterol levels were calculated using Friedewald’s 
equation[17, 18]. The serum levels of fatty acids and sdLDL-cholesterol in fasting blood samples 
were analyzed at SRL Company Ltd. (Tokyo, Japan). In brief, for measuring fatty acids, the lipid 
fraction was extracted from serum into chloroform/methanol using Folch's procedure, and then 
fatty acids (tricosanoic acid, C23:0, as the internal standard) were methylated with boron 
trifluoride and methanol. The methylated fatty acids were then analyzed using a capillary gas 
chromatograph (GC-2010; Shimadzu, Kyoto, Japan) and a BPX70 capillary column (0.25 mm 
internal diameter × 30 m; SGE International Ltd., Melbourne, Australia). We measured n-3 PUFA 
including EPA and docosahexaenoic acid (DHA) and n-6 PUFA including arachidonic acid (AA), 
dihomo-γ-linolenic acid (DGLA). SdLDL-cholesterol was measured using commercially 
available assay kit (sdLDL-EX; Denka Seiken Co.,Tokyo, Japan) as previously described[19].  
Statistical Analysis. 
Continuous variables are expressed as the mean ± standard deviation. Categorical variables 
are expressed as the number and percentage. Differences among the three time points were 
compared by repeated measures analysis of variance (ANOVA) with covariates including age, 
gender, current smoking, hypertension, and diabetes mellitus, and then followed by the 
Bonferroni post-hoc test. A value of p < 0.05 was considered significant. Calculations were 
performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). 
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Results 
The baseline characteristics of the study participants are shown in Table 1. The 10 
participants were all men (mean age, 70 years). The statins used were pravastatin, two patients 
(10 mg/day); atorvastatin, six patients (10 mg/day); and rosuvastatin, two patients (2.5 mg/day). 
Patients with diabetes mellitus accounted for 40%. All patients maintained their body mass index 
during this study (at baseline, 26.1 ± 4.9 kg/m2; at 4 weeks after treatment; 26.2 ± 5.6 kg/m2, and 
at 4 weeks after discontinuation, 26.2 ± 5.2 kg/m2). 
Changes in serum lipids and PUFAs in the 10 patients are shown in Table 2 and Fig 2. 
Ezetimibe treatment for 4 weeks significantly decreased the concentrations of total cholesterol, 
LDL-cholesterol, and sdLDL-cholesterol (Fig 2A), which returned to near baseline levels at 4 
weeks after discontinuation of ezetimibe. The concentration of triglyceride tended to reduce for 4 
weeks of ezetimibe treatment and returned to near baseline levels at 4 weeks after discontinuation 
of ezetimibe. Ezetimibe, however, did not significantly affect HDL-cholesterol, EPA (Fig. 2B), 
DHA, DGLA, or AA levels during the study period (Table 2). Consequently, ezetimibe did not 
affect the ratio of EPA to AA. HemoglobinA1c, serum creatine, and creatine kinase were also did 
not change during this study (Table 2). There were no significant change in systolic blood 
pressure and diastolic blood pressure during this study period (systolic pressure/diastolic pressure 
at baseline, 125 ± 13 / 67 ± 8 mmHg; at 4 weeks after treatment; 126 ± 14 /70 ± 8 mmHg, and at 
4 weeks after discontinuation 124 ±13 /71 ± 9 mmHg). No clinical or laboratory adverse events 
or discontinuation occurred during the study period. 
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Discussion 
This study demonstrated that ezetimibe in addition to statins and EPA significantly decreased 
sdLDL-cholesterol levels, but did not affect the absorption of supplemental EPA in patients with 
CAD. For secondary prevention of CAD, ezetimibe in addition to statins and EPA may be useful 
for controlling residual risks. 
Although the patients in this study achieved considerable reduction in LDL-cholesterol levels 
(<100 mg/dl) with a statin and supplemental EPA, we found that ezetimibe successfully reduced 
LDL-cholesterol levels even further. The fact that sdLDL-cholesterol levels returned to baseline 
values after discontinuation of ezetimibe clearly shows the effect of ezetimibe on lowering 
sdLDL-cholesterol levels. This finding was consistent with previous studies that ezetimibe alone 
or in combination with a statin lowered sdLDL-cholesterol levels in patients with in patients with 
diabetes and glucose intolerance. [11, 12] In contrast, a recent study showed that treatment with 
ezetimibe alone or in combination with a statin increases sdLDL-cholesterol in healthy 
individuals [20]. This data suggested that ezetimibe was associated with the development of a 
pro-atherogenic LDL subfraction profile in subjects with a normal metabolic condition. The 
effect of ezetimibe on sdLDL-cholesterol is still argued, because the lack of clinical evidence of 
ezetimibe in cardiovascular events despite its significant LDL-cholesterol lowering effect; 
however, larger study is warranted to evaluate the effect of ezetimibe on sdLDL-cholesterol in 
patients with hypercholesterolemia or hypertriglyceridemia. Furthermore, our study demonstrates 
that ezetimibe decreases hypertriglyceridemia in patients receiving a statin and supplemental EPA, 
which is consistent with our previous findings that co-administration of ezetimibe and a statin 
reduce triglyceride levels in CAD patients[8]. Thus, ezetimibe in combination with a statin and 
EPA may be useful for reduction of residual risks, especially for secondary prevention of CAD.  
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We also demonstrated that ezetimibe did not affect serum n-3 PUFA concentrations in patients 
receiving supplemental EPA. The mammalian cholesterol-transport protein Niemann-Pick 
C1-like 1 is located on the surface of enterocytes[21]. In mice, ezetimibe treatment or lack of 
Niemann-Pick C1-like 1 significantly reduces absorption of dietary saturated fatty acids, 
particularly stearate and palmitate, but has only a small effect on absorption of the unsaturated 
fatty acids oleate and linoleate[15]. These results are consistent with the effects of ezetimibe on 
the PUFAs that we measured. Conversely, Kurisu et al. recently reported that strong statins 
reduce serum n-3 PUFA concentrations in proportion to the attendant decrease in 
LDL-cholesterol levels[22]. This difference on absorption of n-3 PUFAs by statins and ezetimibe 
is clinically interesting. These results suggest that ezetimibe may be a preferred therapy for 
patients with atherogenic dyslipidemia, however further investigation is needed to determine the 
optimal combination of therapies that will lower sdLDL-cholesterol levels in the absence of 
undesired side effects such as a decrease in n-3 PUFA levels. 
   Previous studies suggested potential beneficial effects of n-3 PUFAs on cardiovascular 
disease [23-25], while recent cardiovascular outcome studies on n-3 PUFA therapy have been 
disappointing [26-28]. One possible reason of this discrepancy was the dose of n-3 PUFA. Harris 
et al. reported that greater fatty acid composition in red blood cell membrane was associated with 
the greater cardioprotection [29]; however, the 2013 AHA/ACC Cardiovascular Risk Reduction 
Guideline does not recommend strongly the supplemental use of n-3 PUFA [30]. Further studies 
are needed to assess n-3 PUFA therapies in the context of clinical care using larger patient 
populations and larger doses, while a lot of epidemiologic studies showed that low n-3 PUFA 
level is a risk of CAD. [31-33] Thus, Inhibition of absorption of n-3 PUFA is not favorable; 
therefore our finding that ezetimibe did not affect EPA level may be informative.  
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Limitations to our study include: 1) this was an open-label add-on study. Evaluation at 4 
weeks after discontinuation of ezetimibe and careful statistical analyses may have compensated 
for this limitation; however, there is no doubt that a larger study, preferably with a double-blind 
crossover, multi-center design, will be required to confirm our findings. 2) We measured the 
concentrations of EPA, DHA, DGLA, and AA, but did not evaluate their proportions relative to 
total free fatty acids. 3) This study included only a small number of patients with CAD on a 
particular combination treatment regimen, making it difficult to generalize the results to other 
populations. 
 
Conclusions 
Ezetimibe in addition to statins and EPA significantly decreased sdLDL-cholesterol, but did 
not affect serum EPA concentrations in patients with CAD. Ezetimibe may be a promising agent 
as an add-on therapy to statins and EPA to reduce residual risks in patients with CAD. 
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Table 1. Participant characteristics. 
Number of patients  10 
Age (years) 70 ± 7 
Body mass index (kg/m2) 26.1 ± 4.9 
Abdominal circumference (cm) 94.5 ± 13.5 
Hypertension 9 (90%) 
Diabetes Mellitus 4 (40%) 
Previous coronary heart disease 7 (70%) 
Fasting blood glucose (mg/dl) 122 ± 20 
Systolic blood pressure (mmHg) 125 ± 13 
Diastolic blood pressure (mmHg) 67 ± 8 
Currently smoking 5 (50%) 
Concomitant medication  
 Eicosapentaenoic acid 10 (100%) 
 Statins  
  Pravastatin 2 (20%) 
  Atorvastatin 6 (60%) 
  Rosuvastatin 2 (20%) 
Antihypertensive agents  
  ACEI/ARBs 9 (90%) 
  Calcium channel blockers 4 (40%) 
  β-blockers 7 (70%) 
 Antidiabetic agents  
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   Insulin 2 (20%) 
   Thiazolidinedione 2 (20%) 
   DPP4 inhibitor 3 (30%) 
   α-Glucosidase inhibitor 1 (10%) 
 
ACEI; angiotensin-converting enzyme inhibitor, ARB; angiotensin II type 1 receptor blocker, 
DPP4; dipeptidyl peptidase 4. 
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Table 2. Serum lipid, polyunsaturated fatty acid levels, and other parameters before ezetimibe, 4 
weeks after starting ezetimibe, and 4 weeks after discontinuation of ezetimibe. 
 Baseline 
4 weeks after 
ezetimibe start 
4 weeks after 
ezetimibe end 
Total Cholesterol 155 ± 17 136 ± 15* 165 ± 26† 
LDL-cholesterol (mg/dl) 81 ± 21 63 ± 15* 86 ± 29† 
HDL-cholesterol (mg/dl) 48 ± 14 50 ± 16 52 ± 16 
Triglyceride (mg/dl) 212 ± 49 168 ± 60 222 ± 99 
sdLDL-cholesterol (mg/dl) 35 ± 13 27 ± 9* 37 ± 13† 
EPA (μg/ml) 213 ± 58 208 ± 83 218 ± 81 
DHA (μg/ml) 170 ± 84 163 ± 89 165 ± 90 
AA (μg/ml) 173 ± 27 186 ± 56 175 ± 24 
DGLA (μg/ml) 32 ± 9 32 ± 6 33 ± 6 
EPA/AA 1.25 ± 0.33 1.15 ± 0.38 1.25 ± 0.43 
HemoglobinA1c (%) 6.5 ± 0.8 6.5 ± 0.7 6.5 ± 0.7 
Serum creatinine (mg/dl) 0.96 ± 0.15 0.91 ± 0.20 0.87 ± 0.20 
Creatine kinase (U/l) 95 ± 52 97 ± 90 104 ± 76 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; sd, small dense; AA, arachidonic 
acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DGLA, dihomo-γ-linolenic acid. 
*, p < 0.05 versus baseline; †, p < 0.05 versus 4 weeks after treatment with ezetimibe. 
Differences among the three time points were compared by repeated measures analysis of 
variance (ANOVA) with covariates including age, current smoking, hypertension, and diabetes 
mellitus, and then followed by the Bonferroni post-hoc test. 
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Legends for Figures 
 
Figure 1. Schema of the study design. EPA; eicosapentaenoic acid. 
 
Figure 2. Effects of ezetimibe on sdLDL- cholesterol andeicosapentaenoic acid in all patients. 
SdLDL- cholesterol levels (A) and eicosapentaenoic acid levels (B) at baseline, 4 weeks after 
start of ezetimibe and 4 weeks after discontinuation of ezetimibe. Open circle indicates the mean 
value. *p<0.05 versus 4 weeks after ezetimibe start. sdLDL, small dense low-density  
lipoprotein. Differences among the three time points were compared by repeated measures 
analysis of variance (ANOVA) with covariates including age, current smoking, hypertension, and 
diabetes mellitus, and then followed by the Bonferroni post-hoc test. 
